For more than 20 years since its establishment, the company has pioneered Chinese product series and successfully developed more than 80 varieties and 200 specifications of single and double biochemical reagents for series of reagent kits, such as liver, lipid, kidney, cardiac, special proteins, trace elements, and glucose metabolism. The diagnostic reagent series was awarded as the fist product of Beijing New Technology Industry Development Pilot Zone in 1990-2000, and was evaluated as Beijing Famous Brand Product in 2002 by Beijing Municipal Bureau of Quality and Technical Supervision and Beijing Municipal Economic Commission, and was awarded as the No.1 Brand of China's Diagnostic Reagent Market for Product Quality, User Satisfaction, Quality and Reputation by People's Daily and other authoritative organizations in 2005. While maintaining the high sales growth of biochemical diagnostic series products, the company has been expanding its product structure to cover all branches of the IVD industry, and successfully developed immuno-diagnostic series products and molecular diagnostic series products, with the manufacturing system becoming more and more perfect.
In 2002, the company passed the ISO9001 quality system certification, and in July 2004, the company successfully passed the ISO13485 medical device quality management system certification, with the most stringent and complete quality system. 2005, the company strictly in accordance with the GMP standard construction of more than 11,000 square meters of new bases, equipped with first-class automated production equipment, to achieve the international advanced management mode. Adopting the international advanced management mode, the company has realized the advanced production process such as microcomputer networking and automated linkage. After more than 20 years of development, CSCNC has more than 500 agents and distributors, with more than 75% of the users in the industry, forming a nationwide sales network and becoming the enterprise with the largest market share in the domestic IVD industry. Meanwhile, the company's series of products have passed the CE certification of the European Union, and the overseas market is expanding.
Since its establishment, CSPC has been taking the responsibility of promoting the development of IVD industry, following the enterprise spirit of "honesty, cooperation, dedication, and innovation", implementing the overall diversified development goals, enriching the product structure, expanding the industrial chain, and improving the quality of products. At present, CSCNC has developed into a group company with several subsidiaries, and its products mainly include two series of in vitro diagnostic products and protein drugs, covering protein peptide drugs (earthworm kinase, etc.), biochemical diagnostic reagents, immunodiagnostic reagents, molecular diagnostic reagents, biochemical analyzers, immunoassay analyzers, rapid diagnostic products for maternal and child health care, gold standard rapid diagnostic products, reference products, and quality control products. diagnostic products for maternal and child health, gold standard rapid diagnostic products, reference products and quality control products.
Facing the future, CBC will grasp new opportunities and meet new challenges, focus on building China's clinical biochemistry and immunoassay systems with independent intellectual property rights and cost-effective international advantages, constantly introduce and absorb advanced technologies, digest them to suit its own advantages and characteristics, adhere to independent innovation as the inexhaustible power of the company's survival and development, and aspire to become the forerunner of the protein industry with international competitiveness. We are aiming to become a pioneer in the protein industry with international competitiveness, to contribute to China's biomedical industry and to serve human health.